Glenmark Launches Teneligliptin + Dapagliflozin Fdc For Adults With Type 2 Diabetes Having Comorbidities
Glenmark Pharmaceuticals Limited (Glenmark), An Innovation-Driven Global Pharmaceutical Company, Became The First To Launch Teneligliptin (20Mg) + Dapagliflozin (5Mg/10Mg) Fixed Dose Combination (Fdc) For The Treatment Of Adult Patients With Type 2 Diabetes, Especially The Ones With Comorbidities. Marketed Under The Brand Name Zita D; It Contains Teneligliptin (20Mg) + Dapagliflozin (5 Mg/10 Mg), And Must Be Taken Once Daily Under Prescription To Improve Glycaemic Control & Prevent Complications In Adult Patients With Type 2 Diabetes, Especially The Ones With Comorbidities. On The Launch, Alok Malik, Evp & Business Head - India Formulations, Glenmark Pharmaceuticals, Said,
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!